Sophia Genetics SA (SOPH) News
Filter SOPH News Items
SOPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SOPH News Highlights
- For SOPH, its 30 day story count is now at 3.
- Over the past 14 days, the trend for SOPH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about SOPH are CRI and DEC.
Latest SOPH News From Around the Web
Below are the latest news stories about SOPHIA GENETICS SA that investors may wish to consider to help them evaluate SOPH as an investment opportunity.
Hôpital Saint-Louis Implements SOPHiA DDM™ Platform to Further Research of Myeloid DisordersSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area. This latest implementation is an expansion of its existing work with SOPHiA GENETICS. |
SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare ConferenceBOSTON and ROLLE, Switzerland, Dec. 14, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (NASDAQ: SOPH) today announced that Jurgi Camblong, PhD., Chief Executive Officer and Co-founder, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PST in San Francisco. Live, listen-only webcasts of this presentation can be accessed by visiting the Investors section of the SOPHiA GENETICS website at ir.sophiagenetics.com. A replay of the webcast will b |
SOPHiA GENETICS Announces Expanded Suite of Liquid Biopsy OfferingsSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced an expanded suite of solutions under SOPHiA DDM™ for Liquid Biopsy. The range of solutions, including MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions, will help progress oncology research and tumor mutation profiling. The rollout of SOPHiA GENETICS' liquid biopsy capabilities demonstrates the company's commitment to developing advanced solutions that empower timely, cri |
SOPHiA GENETICS Announces Expansion of Work with CHU de NîmesSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that it has expanded its work with CHU de Nîmes, a regional and university hospital located in the South of France. The hospital system will use the SOPHiA DDM™ Platform to progress its pharmacogenomics research. |
SOPHiA GENETICS Expands Relationship with Città della Salute e della Scienza di TorinoSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the expansion of its relationship with the Città della Salute e della Scienza di Torino located in Turin, Italy. The hospital, which used SOPHiA GENETICS after a public tender in 2021 to optimize workflows and support research in the areas of hereditary cancer, neurological disorders, solid tumors, hematology and rare disease, will further expand its usage |
The Institute of Human Genetics, Polish Academy of Sciences (IHG PAS) is Live on SOPHiA GENETICSSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform. IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility. |
SOPHiA GENETICS (NASDAQ:SOPH) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
SOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2023 Earnings Call TranscriptSOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today. At this time, I would like to welcome everyone to the SOPHiA GENETICS Third Quarter 2023 Earnings Conference Call. [Operator Instructions] I […] |
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that processes more than 12 million tests annually, will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite. With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™. The |
SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023Record results on growth acceleration, significant improvement in operating loss and cash burnBOSTON and ROLLE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Revenue for the third quarter of 2023 was $16.3 million, representing year-over-year growth of 40% on a reported basis over the correspon |